Continuous glucose monitoring systems are increasingly being adopted as an alternative to self-monitoring of blood glucose/point of care testing (SMBG/POCT) by persons with diabetes receiving insulin therapy.

Flash glucose monitoring is demonstrated to facilitate better glucose monitoring, reduce the event rate of hypoglycemia, and improve quality of life of diabetes patients.

The IQVIA CORE Diabetes Model v9.5 was used to compare the cost-effectiveness of flash glucose monitoring versus SMBG/POCT for both patients with type 1 and patients with type 2 diabetes from a Chinese societal perspective.

The analyses showed that flash glucose monitoring was cost-effective compared with SMBG/POCT, with an incremental cost-effectiveness ratio of Chinese yuan (CNY) 47,636 per quality-adjusted life years gained in patients with type 1 diabetes and CNY 140,297 per quality-adjusted life years gained in patients with type 2 diabetes.

Scenario analyses further demonstrated that flash glucose monitoring was likely to be an optimal option from both health outcomes and economic considerations compared to SMBG/POCT.